SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (13042)9/18/2004 12:29:57 AM
From: rkrw  Respond to of 52153
 
I should have said give credit to clinical and licensing group.

Yes, approved in eu for years but idev still licensed and ran extensive US trials, meanwhile a couple of big rx have OAB drugs delayed at the fda.

It's about i/d opportunities and executing the clinicals. idev scores for both.



To: Michael Young who wrote (13042)9/19/2004 7:41:47 PM
From: Miljenko Zuanic  Respond to of 52153
 
Than what is special about CEPH and Modafinil? BTW, CEPH management screwed investors several times, before they got lucky.

It is ALL about glasses and angle.

Miljenko

PS: Modafinil does not have competition (yet), but Sanctura do.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News